Summary
Merck & Co., Inc. reported a significant decrease in sales and net income for the second quarter and first six months of 2013 compared to the prior year. This downturn was primarily driven by the loss of market exclusivity for key products, most notably Singulair, following patent expiries in the U.S. and major European markets. The company also faced challenges from ongoing healthcare cost containment measures and unfavorable foreign exchange rates. Despite the top-line decline, Merck continued to invest in its research and development pipeline, with notable progress in allergy immunotherapy and oncology. The company also initiated substantial share repurchase programs, financed partly by new debt issuance, signaling a focus on returning capital to shareholders. Investors should closely monitor the impact of patent expirations on key products, the performance of newer drugs and vaccines, and the company's ongoing restructuring efforts to improve efficiency.
Financial Highlights
50 data points| Revenue | $11.01B |
| Cost of Revenue | $4.28B |
| Gross Profit | $6.73B |
| R&D Expenses | $2.10B |
| SG&A Expenses | $3.14B |
| Interest Expense | $201.00M |
| Net Income | $906.00M |
| EPS (Basic) | $0.30 |
| EPS (Diluted) | $0.30 |
| Shares Outstanding (Basic) | 2.98B |
| Shares Outstanding (Diluted) | 3.01B |
Key Highlights
- 1Total sales decreased by 11% in Q2 2013 and 10% for the first six months of 2013 compared to the prior year, largely due to the loss of Singulair exclusivity.
- 2Net income attributable to Merck & Co., Inc. fell significantly, with Q2 2013 net income at $906 million ($0.30 EPS) versus $1,793 million ($0.59 EPS) in Q2 2012.
- 3The company recorded substantial restructuring costs totaling $278 million in Q2 2013 and $472 million for the first six months of 2013, primarily related to the post-merger integration.
- 4Research and development expenses remained relatively stable year-over-year, with a slight decrease in Q2 2013, indicating continued investment in pipeline development.
- 5Merck announced and initiated significant share repurchase programs, including a $5 billion accelerated share repurchase (ASR), financed by new debt issuance.
- 6Sales of key growth drivers like Gardasil and Januvia showed mixed performance, with Gardasil sales up 18% in Q2, while Januvia sales saw a 1% decline in Q2.
- 7The company recognized significant intangible asset impairment charges, including $330 million for Saphris/Sycrest and $181 million for preladenant due to clinical development discontinuation.